Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT03730129

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity

Sponsor: Rochester General Hospital

Conditions Secondary Immune Deficiency Disorder

Interventions Hizentra

Updated 5 times since 2018 Last updated: Aug 25, 2020 Started: Nov 5, 2018 Primary completion: Jul 3, 2020 Completion: Jul 3, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Secondary Immune Deficiency Disorder, this trial is completed. The trial is conducted by Rochester General Hospital and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Dec 2018 — Sep 2020 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rochester General Hospital

Data source: Rochester General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States